NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market Tuesday that its fourth-quarter revenues increased 364 percent year over year, driven by reagent sales from greater system placements.

The Carlsbad, Calif.-based molecular diagnostics firm had total revenues of $9.4 million for the three months ended Dec. 31, compared to $2 million for the fourth quarter of 2011. Its reagent sales were up more than 400 percent to $9.1 million from $1.8 million, while its instrument and other revenues climbed 39 percent to $312,000 from $224,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.